Early-Stage brain cancer trial aims to see if drug hits the target
NCT ID NCT05076513
Summary
This early-stage study is testing a drug called niraparib for two types of aggressive brain cancer. It first checks if the drug reaches the tumor effectively after a short pre-surgery dose. If it does, participants can continue taking the drug, sometimes with radiation, to try to slow the cancer's return. The goal is to see if this approach helps control the disease and delay its progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013, United States
Conditions
Explore the condition pages connected to this study.